Sinopharm : ANNOUNCEMENT PRINCIPAL FINANCIAL DATA OF SINOPHARM ACCORD FOR THE YEAR ENDED 31 DECEMBER 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT

PRINCIPAL FINANCIAL DATA OF SINOPHARM ACCORD

FOR THE YEAR ENDED 31 DECEMBER 2020

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the "Company") dated 1 April 2021 (the "Announcement") in relation to the annual report for the year ended 31 December 2020 of China National Accord Medicines Corporation Ltd. ("Sinopharm Accord"), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code: 000028 for A shares; 200028 for B shares) (collectively with its subsidiaries, the "Sinopharm Accord Group").

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal audited financial data of the Sinopharm Accord for the year ended 31 December 2020 as set out in the Announcement.

PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD

Unit: Unless otherwise stated, in RMB yuan

Whether it has retroactive adjustment or restatement on previous accounting data or not

• Yes □ No

Reasons of retroactive adjustment or restatement

Enterprise merger under same control (Note 1)

				Changes of
				this year
		The year of 2019	compared	The year of 2018
	The year of 2020			with last
				year
		Before adjustment	After adjustment	After	Before	After adjustment
		adjustment	adjustment
Revenue	59,649,455,012.03	52,045,764,143.21	52,786,807,476.28	13.00%	43,122,385,521.23	43,858,500,106.45
Net profit attributable
to shareholders of the	1,401,892,593.23	1,271,289,183.01	1,267,931,291.32	10.57%	1,210,742,435.78	1,208,343,941.71
listed company
Net profit attributable
to shareholders of the
listed company after	1,369,652,035.50	1,226,765,271.97	1,226,765,271.97	11.65%	1,175,971,967.39	1,175,971,967.39
deducting non-
recurring gains and
losses (Note 2)
Net cash flow arising
from operating	1,502,746,598.47	2,000,352,083.20	2,012,653,189.74	-25.34%	1,322,606,352.27	1,338,639,227.25
activities
Basic earnings per
share (RMB/Share)	3.27	2.97	2.96	10.47%	2.83	2.82
(Note 2)
Diluted earnings per	3.27	2.97	2.96	10.47%	2.83	2.82
share (RMB/Share)
				increased by
Weighted average ROE	10.49%	10.43%	10.31%	0.18	11.56%	11.41%
(Note 2)	percentage
				point
				Changes of
				2020
	At the end of	At the end of 2019	year-end	At the end of 2018
			over 2019
	2020
			year-end
		Before adjustment	After adjustment	After	Before	After adjustment
		adjustment	adjustment
Total assets	39,594,533,471.65	33,520,609,123.67	34,028,843,214.20	16.36%	28,930,300,519.97	29,450,897,487.81
Net assets attributable
to shareholders of the	13,948,322,652.33	12,806,410,865.92	12,911,140,435.88	8.03%	11,618,432,603.28	11,726,520,064.93
listed company

Note 1: In 2020, Sinopharm Accord Group acquired 75.00% equity interest in Shanghai Pudong New Area Medical Materials Co., Ltd. (上海浦東新區醫藥藥材有限公司, "Shanghai Pudong") which is under the same control as the Sinopharm Accord Group. When preparing the comparison table of the consolidated financial statements of Sinopharm Accord Group for the year 2020, it is deemed that Sinopharm Accord Group has consolidated the financial statements of Shanghai Pudong from the date when the ultimate controller of the parties to the transaction controlled Shanghai Pudong, and the financial data of the same period last year is so adjusted.

Note 2: The net profit attributable to the shareholders of the listed company for the reporting period

increased by 10.57% as compared to the same period last year, which is mainly due to the increase in the sales scale of pharmaceutical retail business of Sinopharm Accord Group as well as the incremental performance brought by acquired companies. As a result, the basic earnings per share has increased by 10.47% as compared to the same period last year, and the weighted average ROE increased by 0.18 percentage point as compared to the same period last year.

By order of the Board

Sinopharm Group Co. Ltd.

Yu Qingming

Chairman

Shanghai, the PRC

1 April 2021

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.

• The Company is registered as a non-Hong Kong company under the Hong Kong Companies
  Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".